TY - JOUR
T1 - Dendritic Cells
T2 - A Critical Player in Cancer Therapy?
AU - Palucka, Anna Karolina
AU - Ueno, Hideki
AU - Fay, Joseph
AU - Banchereau, Jacques
PY - 2008
Y1 - 2008
N2 - Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit. It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or active, that is, vaccination. Early clinical trials testing vaccination with ex vivo generated dendritic cells (DCs) pulsed with tumor antigens provide a proof-of-principle that therapeutic immunity can be elicited. Yet, the clinical benefit measured by regression of established tumors in patients with stage IV cancer has been observed in a fraction of patients only. The next generation of DC vaccines is expected to generate large numbers of high avidity effector CD8+ T cells and to overcome regulatory T cells and suppressive environment established by tumors, a major obstacle in metastatic disease. Therapeutic vaccination protocols will combine improved DC vaccines with chemotherapy to exploit immunogenic chemotherapy regimens. We foresee adjuvant vaccination in patients with resected tumors but at high risk of relapse to be based on in vivo targeting of DCs with fusion proteins containing anti-DCs antibodies, antigens from tumor stem/propagating cells, and DC activators.
AB - Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit. It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or active, that is, vaccination. Early clinical trials testing vaccination with ex vivo generated dendritic cells (DCs) pulsed with tumor antigens provide a proof-of-principle that therapeutic immunity can be elicited. Yet, the clinical benefit measured by regression of established tumors in patients with stage IV cancer has been observed in a fraction of patients only. The next generation of DC vaccines is expected to generate large numbers of high avidity effector CD8+ T cells and to overcome regulatory T cells and suppressive environment established by tumors, a major obstacle in metastatic disease. Therapeutic vaccination protocols will combine improved DC vaccines with chemotherapy to exploit immunogenic chemotherapy regimens. We foresee adjuvant vaccination in patients with resected tumors but at high risk of relapse to be based on in vivo targeting of DCs with fusion proteins containing anti-DCs antibodies, antigens from tumor stem/propagating cells, and DC activators.
KW - Cancer vaccines
KW - Chemotherapy
KW - Dendritic cells
KW - Immunotherapy
KW - T cells
UR - http://www.scopus.com/inward/record.url?scp=67650105908&partnerID=8YFLogxK
U2 - 10.1097/CJI.0b013e31818403bc
DO - 10.1097/CJI.0b013e31818403bc
M3 - Review article
C2 - 18833008
AN - SCOPUS:67650105908
SN - 1524-9557
VL - 31
SP - 793
EP - 805
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
IS - 9
ER -